BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37296316)

  • 1. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.
    Yang D; Zhao F; Su Y; Zhou Y; Shen J; Yu B; Zhao K; Ding Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10609-10621. PubMed ID: 37296316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
    Feng Q; Huang Z; Song L; Wang L; Lu H; Wu L
    Eur J Med Res; 2023 Aug; 28(1):306. PubMed ID: 37649103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
    Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
    Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model.
    Yang D; Zhou Y; Zhang Y; Su Y; Shen J; Yu B; Zhao K; Ding Y
    Cancer Immunol Immunother; 2023 Dec; 72(12):4323-4335. PubMed ID: 38006433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
    Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
    BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of single-cell and bulk RNA-sequencing reveals a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in gastric cancer.
    Sun JR; Kong CF; Ye YX; Wang Q; Qu XK; Jia LQ; Wu S
    Sci Rep; 2024 Apr; 14(1):7648. PubMed ID: 38561388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of NK Marker Genes in Ovarian Cancer by scRNA-seq Combined with WGCNA Algorithm.
    He X; Feng W
    Mediators Inflamm; 2023; 2023():6845701. PubMed ID: 37144238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
    Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
    Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.
    Guo C; Tang Y; Li Q; Yang Z; Guo Y; Chen C; Zhang Y
    Comput Biol Med; 2023 May; 158():106872. PubMed ID: 37030269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
    Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
    Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
    Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
    Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of single-cell and bulk RNA-sequencing reveals tumor heterogeneity and a signature based on NK cell marker genes for predicting prognosis in hepatocellular carcinoma.
    Li S; Du H; Gan D; Li X; Zao X; Ye Y
    Front Pharmacol; 2023; 14():1200114. PubMed ID: 37397471
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined analysis of bulk and single-cell RNA sequencing reveals novel natural killer cell-related prognostic biomarkers for predicting immunotherapeutic response in hepatocellular carcinoma.
    Zhang K; Yuan E
    Front Immunol; 2023; 14():1142126. PubMed ID: 37056756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma.
    Li J; Li Y; Li F; Xu L
    Sci Rep; 2023 May; 13(1):7294. PubMed ID: 37147523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
    Xiong X; Song Q; Jing M; Yan W
    Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing.
    Song P; Li W; Guo L; Ying J; Gao S; He J
    Front Immunol; 2022; 13():850745. PubMed ID: 35757748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.